Copyright
©The Author(s) 2016.
World J Gastroenterol. May 28, 2016; 22(20): 4812-4823
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4812
Published online May 28, 2016. doi: 10.3748/wjg.v22.i20.4812
Ref. | Arms | n | TTP/PFS (mo) | OS (mo) |
Van Cutsem et al[7] | DCF vs CF | 445 | TTP: 5.6 vs 3.7 | 9.2 vs 8.6 |
P < 0.001 | P = 0.02 | |||
Al-Batran et al[8] | FLO vs FLP | 220 | PFS: 5.8 vs 3.9 | 10.7 vs 8.8 |
P = 0.077 | ||||
REAL-2[9] | ECF vs ECX vs EOF vs EOX | 1002 | PFS: 6.2 vs 6.7 vs 6.5 vs 7.0 | 9.9 vs 9.9 vs 9.3 vs 11.2 |
Kang et al[10] | XP vs FP | 316 | PFS: 5.6 vs 5.0 | 10.5 vs 9.3 |
SPIRITS[11] | CS vs S-1 | 298 | PFS: 6.0 vs 4.0 | 13.0 vs 11.0 |
P < 0.0001 | P = 0.04 | |||
FLAGS[12] | CS vs CF | 1053 | PFS: 4.8 vs 5.5 | 8.6 vs 7.9 |
P = 0.920 | P = 0.20 | |||
Dank et al[13] | IF vs CF | 333 | TTP: 5.0 vs 4.2 | 9.0 vs 8.7 |
P = 0.088 | ||||
Guimbaud et al[14] | FOLFIRI vs ECX | 416 | PFS: 5.3 vs 5.8 | 9.5 vs 9.7 |
P = 0.960 | P = 0.95 |
- Citation: Jou E, Rajdev L. Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol 2016; 22(20): 4812-4823
- URL: https://www.wjgnet.com/1007-9327/full/v22/i20/4812.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i20.4812